Morphine
ArticlesMedicine Compliance Aid StabilityLactation Safety Information · Published , updated
73572009
Articles
10 November 2020
What is the risk of interaction between opioids and monoamine oxidase inhibitors (MAOIs)?
**THIS ARTICLE IS CURRENTLY UNDER REVIEW** Interactions Isocarboxazid Linezolid Mental Health Mental health and illness Methylthioninium chloride Moclobemide Morphine Phenelzine Rasagiline Selegiline Tranylcypromine
9 November 2020
What are the equivalent doses of oral morphine to other oral opioids when used as analgesics in adult palliative care?
Morphine is generally the strong opioid of choice for treating moderate to severe cancer pain and a common question is how to convert a dose… Anaesthesia and pain Cancers Codeine Dihydrocodeine Dosing Guidance Hydromorphone Morphine Oxycodone Palliative and End of Life Care Switching Tapentadol Tramadol
21 October 2020
Safety in Lactation: Opioid analgesics
The evidence relating to the safe use of opioid analgesics in breastfeeding mothers is very variable between individual drugs. This group of drugs presents a… Buprenorphine Codeine Diamorphine Dihydrocodeine Dipipanone + Cyclizine Fentanyl Hydromorphone Meptazinol Methadone Morphine Oxycodone Papaveretum Pethidine Tapentadol Tramadol
8 September 2020
Supply and/or administration of Controlled Drugs under a Patient Group Direction
This Q&A summarises the legal position on the supply and/or administration of controlled drugs under PGDs. Diamorphine Ketamine Medicines Safety Midazolam Morphine Patient Group Directions Regulatory Tramadol
7 May 2020
Can opioids be used for pain relief during pregnancy?
There are no specific guidelines for the treatment of pain in pregnancy. Not all analgesics are suitable for use during or at certain stages of… Anaesthesia and pain Codeine Dihydrocodeine Morphine Obstetrics and gynaecology Oxycodone Tapentadol Tramadol
19 December 2019
What naloxone doses should be used in adults to urgently reverse the effects of opioids?
The opioid antagonist, naloxone, is a highly effective antidote the use of which is potentially life-saving. The drug has a role in a wide range… Buprenorphine Diamorphine Dosing Emergency medicine and urgent care Fentanyl Medicines Safety Methadone Morphine Naloxone Oxycodone Palliative and End of Life Care Pethidine
12 April 2019
Review of high dose opioids in chronic non-malignant pain
The Faculty of Pain Medicine (Royal College of Anaesthetists) states that the morphine dose for which harms outweigh benefits is 120mg oral morphine or equivalent/24… Best Practice Sharing Buprenorphine Codeine Diamorphine Dihydrocodeine Fentanyl Hydromorphone Medicines Safety Morphine Oxycodone Tramadol
18 October 2018
How should medicines be dosed in children who are obese?
Obesity results in physiological changes that can affect the volume of distribution and the clearance of drugs. The extent of these changes is variable and… Aciclovir Aminophylline Benzylpenicillin Carbamazepine Clindamycin Dosing Enoxaparin Esomeprazole Gentamicin Heparin Ibuprofen Metronidazole Morphine Omeprazole Ondansetron Paediatrics and neonates Paracetamol Phenobarbital Phenobarbital sodium Phenoxymethylpenicillin Phenytoin Phenytoin sodium Prednisolone Ranitidine Theophylline Tobramycin Vancomycin
25 March 2011
ARCHIVED NPSA Signal – Intravenous morphine administration in neonatal units – March 2011
Key risks emerging from the review of serious incidents reported by the NHS to its National Reporting and Learning System (NRLS) were shared in in… Medicines Safety Morphine Paediatrics and neonates
25 May 2006
ARCHIVED NPSA Alert – High dose morphine and diamorphine injections 2006
This page forms part of a resource on medication related patient safety alerts issued by the National Patient Safety Agency (NPSA) between 2002 and 2012… Diamorphine Dosing Medicines Safety MorphineMedicine Compliance Aid Stability
ZomorphArchimedes Pharma UK Ltd
Archimedes Pharma UK Ltd
Zomorph
Capsules m/r - various strengths
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
Protect from moisture
Protect from heat
Protect from moisture and heat.
11 May 2015
SevredolNapp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
Sevredol
Tablets f/c - various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light.
11 May 2015
Filnarine SRTeva Pharmaceuticals Ltd
Teva Pharmaceuticals Ltd
Filnarine SR
Tablets f/c, m/r various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
No special precautions for storage
No special precautions for storage.
11 May 2015
Morphgesic SRAmdipharm Mercury Co Ltd
Amdipharm Mercury Co Ltd
Morphgesic SR
Tablets f/c, m/r various strengths
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
Airtight container
Protect from light
Airtight container and protect from light.
11 May 2015
MST ContinusNapp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
MST Continus
Tablets f/c, m/r various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light
11 May 2015
MXLNapp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
MXL
Capsules m/r - various strengths
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special precautions for storage
11 May 2015
Lactation Safety Information
Except for low dose, immediate release oral formulations
Except for low dose, immediate release oral formulations
Other appropriate analgesic
Significant published evidence of use in breastfeeding
Small amounts in breast milk
Used in full-term neonates from birth
Infant monitoring advised, especially in young infants (see summary)
23 September 2020
Low dose, immediate release oral formulations
Low dose, immediate release oral formulations
Significant published evidence of use in breastfeeding
Small amounts in breast milk
Applies to short term, low dose (up to 10mg 4-hourly) oral solutions (e.g. Oramorph) and tablets
Although adverse effects in infant are not likely infant monitoring advised in young infants (see summary)
23 September 2020